[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-279440-105":53,"doc-detail-279440-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","mycapssa-starter-kit-getting-started-guide","MYCAPSSA Starter Kit - Getting Started Guide","","MYCAPSSA (octreotide) delayed-release capsules are presented for long-term maintenance treatment of acromegaly in patients who have responded to and tolerated prior octreotide or lanreotide therapy. The guide explains contraindications, warnings, and key safety monitoring needs including gallbladder issues, blood sugar and thyroid levels, vitamin B12, and potential bradycardia or gastrointestinal effects. It also outlines common adverse reactions, important drug interactions, and pregnancy counseling, then provides step-by-step onboarding with prescription and patient consent forms plus prior authorization and access support.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/mycapssa-starter-kit-getting-started-guide/279440/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/mycapssa-starter-kit-getting-started-guide/279440.png","ImageObject",442,249,{"name":88,"@type":89},"Lucas Martin","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-19","2026-09-16",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",7,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is MYCAPSSA indicated for in acromegaly treatment?","Question",{"text":109,"@type":110},"MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What safety monitoring is recommended while taking MYCAPSSA?",{"text":114,"@type":110},"Monitor blood sugar, thyroid levels, and vitamin B12, and monitor for gallbladder problems. Evaluate new or worsening GI symptoms for potential pancreatic exocrine insufficiency.",{"name":116,"@type":107,"acceptedAnswer":117},"Which drug interactions may require monitoring or dose adjustment with MYCAPSSA?",{"text":118,"@type":110},"Cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4 may require monitoring and possible dose adjustment.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},279440,1790618408,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":136,"language":137,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":61,"update_tm":141,"read_time":15},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","In the long-term treatment of acromegaly  \nMAKE YOUR MOVE TOMYCAPSSA  \nMYCAPSSA is the oral octreotide that treats acromegaly all day, every day.*  \n*When taken as directed.  \nSTARTER KIT  \nINDICATION AND IMPORTANT SAFETY INFORMATION  \nINDICATION AND USAGE  \nMYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.  \nPlease see additional Important Safety Information throughout and accompanying full Prescribing Information.  \nConsistent control for patients with acromegaly with daily oral MYCAPSSA®  \nWhat’s inside  \nChiesi Total Care Program Overview  \nGetting a Patient Started on MYCAPSSA  \n• Prescription form  \n• Patient enrollment and consent form  \nMYCAPSSA Prior Authorization and Access Guide  \n• Medical necessity letter template  \n• Appeal letter template  \n• Prior authorization submission checklist  \nMYCAPSSA Dosing and Administration Guide  \nCopay Support Information  \nPlease refer to the full Terms and Conditions in the pocket for additional eligibility requirements.  \nUS Prescribing Information  \nContact Information Card  \nINDICATION AND IMPORTANT SAFETY INFORMATION  \nINDICATION AND USAGE  \nMYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.  \nCONTRAINDICATIONS  \nHypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.  \nWARNINGS AND PRECAUTIONS  \nMYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.  \nBlood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.  \nNew onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.  \nADVERSE REACTIONS  \nThe most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.  \nDRUG INTERACTIONS  \nThe following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4 . Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.  \nPatients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.  \nPREGNANCY  \nAdvise premenopausal females of the potential for an unintended pregnancy.  \n[Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA](Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA)[ ](Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA)[at 1-800-FDA-1088 or www.fda.gov/medwatch](at 1-800-FDA-1088 or www.fda.gov/medwatch).  \nPlease see additional Important Safety Information and accompanying full Prescribing Information.  \nFor more information, [visit mycapssa.com](visit mycapssa.com).  \nChiesi Total CareSM Program offered through PANTHERx Rare PharmacySM.  \n©Chiesi USA, Inc. 2025. All rights reserved.  \nMYCAPSSA®","cbCaioFlz8R7srzp","https://ap.wps.com/l/cbCaioFlz8R7srzp","pdf",29328692,34,"English","# Getting Started Guide\n## Getting a Patient Started on MYCAPSSA\n## Prescription and Patient Consent Forms\n## Prior Authorization and Access Guide\n## Dosing and Administration Guide\n## Copay Support Information","[{\"question\":\"What is MYCAPSSA indicated for in acromegaly treatment?\",\"answer\":\"MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.\"},{\"question\":\"What safety monitoring is recommended while taking MYCAPSSA?\",\"answer\":\"Monitor blood sugar, thyroid levels, and vitamin B12, and monitor for gallbladder problems. Evaluate new or worsening GI symptoms for potential pancreatic exocrine insufficiency.\"},{\"question\":\"Which drug interactions may require monitoring or dose adjustment with MYCAPSSA?\",\"answer\":\"Cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4 may require monitoring and possible dose adjustment.\"}]","MYCAPSSA Starter Kit - Getting Started Guide | PDF",1789520780]